Telomerase reverse transcriptase inhibition stimulates cyclooxygenase 2 expression in cancer cells and synergizes with celecoxib to exert anti-cancer effects

British Journal of Cancer

Volumn 108, Issue 11, 2013, Pages 2272-2280

  Liu, T ^a,b   Liang, X ^b   Li, B ^a,b   Bjorkholm M ^a   Jia, J ^b   Xu, D ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Celecoxib; COX2; Htert; Telomerase

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PYRAZOLE DERIVATIVE; SMALL INTERFERING RNA; SULFONAMIDE; TELOMERASE; TERT PROTEIN, HUMAN;

ANIMAL; ARTICLE; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SCREENING; ENZYMOLOGY; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MOUSE; PROMOTER REGION; STOMACH TUMOR; TELOMERE; UPREGULATION; UTERINE CERVIX TUMOR;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG SYNERGISM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROMOTER REGIONS, GENETIC; PYRAZOLES; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; SULFONAMIDES; TELOMERASE; TELOMERE; TRANSFECTION; UP-REGULATION; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884161672     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.208     Document Type: Article

References (47)

1. Adhim Z, Matsuoka T, Bito T, Shigemura K, Lee KM, Kawabata M, Fujisawa M, Nibu K, Shirakawa T (2011) In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines. Br J Cancer 105: 393–402.
2. Blackburn EH (2001) Switching and signaling at the telomere. Cell 106: 661–673.
3. Blackburn EH, Greider CW, Szostak JW (2006) Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med 12: 1133–1138.
4. Boukamp P, Mirancea N (2007) Telomeres rather than telomerase a key target for anti-cancer therapy? Exp Dermatol 16: 71–79.
5. Cao Y, Li H, Deb S, Liu JP (2002) TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene 21: 3130–3138.
6. Chen H, Li Y, Tollefsbol TO (2009) Strategies targeting telomerase inhibition. Mol Biotechnol 41: 194–199.
7. Chen S, Cao W, Yue P, Hao C, Khuri FR, Sun SY (2011) Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3. Cancer Res 71: 6270–6281.
8. Chung LY, Tang SJ, Sun GH, Chou TY, Yeh TS, Yu SL, Sun KH (2012) Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clin Cancer Res 18: 4037–4047.
9. Cong Y, Shay JW (2008) Actions of human telomerase beyond telomeres. Cell Res 18: 725–732.
10. Crawford YG, Gauthier ML, Joubel A, Mantei K, Kozakiewicz K, Afshari CA, Tlsty TD (2004) Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program. Cancer Cell 5: 263–273.
11. Dudognon C, Pendino F, Hillion J, Saumet A, Lanotte M, Segal-Bendirdjian E (2004) Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance. Oncogene 23: 7469–7474.
12. Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, Bursi S, Allegrini G, Fontana E, Di Marsico R, Antonuzzo A, D’Arcangelo M, Danesi R, Del Tacca M, Falcone A, Bocci G (2009) Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 15: 4954–4962.
13. Gauthier ML, Pickering CR, Miller CJ, Fordyce CA, Chew KL, Berman HK, Tlsty TD (2005) p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue. Cancer Res 65: 1792–1799.
14. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA (1999a) Creation of human tumour cells with defined genetic elements. Nature 400: 464–468.
15. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Beijersbergen RL, Knoll JH, Meyerson M, Weinberg RA (1999b) Inhibition of telomerase limits the growth of human cancer cells Nat Med 5: 1164–1170.
16. Harley CB (2008) Telomerase and cancer therapeutics. Nat Rev Cancer 8: 167–179.
17. Hoffmeyer K, Raggioli A, Rudloff S, Anton R, Hierholzer A, Del Valle I, Hein K, Vogt R, Kemler R (2012) Wnt/beta-catenin signaling regulates telomerase in stem cells and cancer cells. Science 336: 1549–1554.
18. Inoue H, Nakata R (2011) Techniques used to study regulation of cyclooxygenase-2 promoter sites. Methods Mol Biol 644: 11–20.
19. Katsukawa M, Nakata R, Takizawa Y, Hori K, Takahashi S, Inoue H (2010) Citral, a component of lemongrass oil, activates PPARalpha and gamma and suppresses COX-2 expression. Biochim Biophys Acta 1801: 1214–1220.
20. Khan Z, Khan N, Tiwari RP, Sah NK, Prasad GB, Bisen PS (2011) Biology of Cox-2: an application in cancer therapeutics. Curr Drug Targets 12: 1082–1093.
21. Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MK, Venning G (2011) Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer 105: 1107–1113.
22. Lindvall C, Hou M, Komurasaki T, Zheng C, Henriksson M, Sedivy JM, Bjorkholm M, Teh BT, Nordenskjold M, Xu D (2003) Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. Cancer Res 63: 1743–1747.
23. Liu L, Liu C, Lou F, Zhang G, Wang X, Fan Y, Yan K, Wang K, Xu Z, Hu S, Bjorkholm M, Xu D (2011) Activation of telomerase by seminal plasma in malignant and normal cervical epithelial cells. J Pathol 225: 203–211.
24. Liu Z, Li Q, Li K, Chen L, Li W, Hou M, Liu T, Yang J, Lindvall C, Bjorkholm M, Jia J, Xu D (2012) Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene 2012; e-pub ahead of print 8 October 2012; doi:10.1038/ onc.2012.441.
25. Massard C, Zermati Y, Pauleau AL, Larochette N, Metivier D, Sabatier L, Kroemer G, Soria JC (2006) hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway. Oncogene 25: 4505–4514.
26. Nardone G, Rocco A, Vaira D, Staibano S, Budillon A, Tatangelo F, Sciulli MG, Perna F, Salvatore G, Di Benedetto M, De Rosa G, Patrignani P (2004) Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori-related gastric carcinogenesis. J Pathol 202: 305–312.
27. Park JI, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M, Chang W, Meng Z, Cheung P, Ji H, McLaughlin M, Veenstra TD, Nusse R, McCrea PD, Artandi SE (2009) Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 460: 66–72.
28. Regalo G, Canedo P, Suriano G, Resende C, Campos ML, Oliveira MJ, Figueiredo C, Rodrigues-Pereira P, Blin N, Seruca R, Carneiro F, Machado JC (2006) C/EBPbeta is over-expressed in gastric carcinogenesis and is associated with COX-2 expression. J Pathol 210: 398–404.
29. Sarin KY, Cheung P, Gilison D, Lee E, Tennen RI, Wang E, Artandi MK, Oro AE, Artandi SE (2005) Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature 436: 1048–1052.
30. Schieven GL (2009) The p38alpha kinase plays a central role in inflammation. Curr Top Med Chem 9: 1038–1048.
31. Shay JW, Keith WN (2008) Targeting telomerase for cancer therapeutics. Br J Cancer 98: 677–683.
32. Shay JW, Wright WE (2007) Hallmarks of telomeres in ageing research. J Pathol 211: 114–123.
33. Simmons DL, Botting RM, Hla T (2004) Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56: 387–437.
34. Smith LL, Coller HA, Roberts JM (2003) Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol 5: 474–479.
35. Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M (2010) The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol 2010: 215158.
36. Stewart SA, Hahn WC, O’Connor BF, Banner EN, Lundberg AS, Modha P, Mizuno H, Brooks MW, Fleming M, Zimonjic DB, Popescu NC, Weinberg RA (2002) Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA 99: 12606–12611.
37. Subbaramaiah K, Chung W, Dannenberg AJ (1998) Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways. J Bio Chem 273: 32943–32949.
38. Sun H, Xu B, Inoue H, Chen QM (2008) P38 MAPK mediates COX-2 gene expression by corticosterone in cardiomyocytes. Cell Signal 20: 1952–1959.
39. Tauchi T, Shin-ya K, Sashida G, Sumi M, Okabe S, Ohyashiki JH, Ohyashiki K (2006) Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene 25: 5719–5725.
40. Tenhunen O, Rysa J, Ilves M, Soini Y, Ruskoaho H, Leskinen H (2006) Identification of cell cycle regulatory and inflammatory genes as predominant targets of p38 mitogen-activated protein kinase in the heart. Circ Res 99: 485–493.
41. Wang D, Dubois RN (2004) Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 31: 64–73.
42. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham D, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA. An ad hoc committee of the National Cancer Research Institute (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555–1577.
43. Wu WK, Sung JJ, Lee CW, Yu J, Cho CH (2010) Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett 295: 7–16.
44. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO (1999) Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 13: 2388–2399.
45. Zhang Y, Toh L, Lau P, Wang X (2012) Telomerase reverse transcriptase (TERT) is a novel target of Wnt/beta-catenin pathway in human cancer. J Biol Chem 287: 32494–32511.
46. Zheng X, Cui XX, Avila GE, Huang MT, Liu Y, Patel J, Kong AN, Paulino R, Shih WJ, Lin Y, Rabson AB, Reddy BS, Conney AH (2007) Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin Cancer Res 13: 5480–5487.
47. This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.